- Real-world use of the implanted continuous glucose monitoring (CGM) system Eversense for 180 days was associated with significant improvements in glycemic control among adults with type 1 diabetes (T1D).
Why this matters
- CGM use in T1D is increasing, but device-related issues including insertion difficulty, discomfort, need for frequent changes, and skin irritation represent barriers for some.
- Prospective observational study of 100 adult first-time Eversense users with T1D at 7 Italian diabetes-care centers.
- Time in range (TIR) defined as glucose 70-180 mg/dL.
- Funding: None.
- Overall HbA1c declined from mean baseline 7.4% (57 mmol/mol) to 6.9% (52 mmol/mol) at 180 days (mean change, −0.43% [5 mmol/mol]; P<.0001>
- The greatest HbA1c reductions occurred in CGM-naive patients and those using insulin pumps (−0.74% [8 mmol/mol]) or multiple daily injections (−0.53% [5 mmol/mol]).
- Overall mean TIR improved from 63% to 69% (P<.0001 with greatest improvements in the cgm-naive.>
- Similar improvements observed for time above range and mean glucose, but no difference in time below range.
- 2 adverse events occurred: mild incision site infection and sensor removal difficulty.
- Mean sensor duration was 163 days.
- No control group.
- Only 1 180-day cycle studied.
- Relatively low baseline HbA1c.
- Small numbers in some subgroups.
- QoL not surveyed.